Acquirer(s)
- Qiagen N.V
Target(s)
- Cellestis Limited
Summary
Qiagen N.V (Qiagen) proposed to acquire Cellestis Limited (Cellestis)Market definition
The ACCC did not consider it necessary to form a concluded view in relation to market definition. Nonetheless, the ACCC considered the competitive effects of the proposed acquisition in the context of a national market for the supply of testing products for latent tuberculosis diagnosis and a national market for the supply of molecular DNA testing products for active tuberculosis diagnosis.Competition analysis
The ACCC concluded that the proposed acquisition was not likely to substantially lessen competition in any relevant market for the following reasons:- the testing products supplied by Qiagen and Cellestis were not substitutable and there was unlikely to be any horizontal overlap in their operations in the foreseeable future;
- Qiagen and Cellestis did not appear to have significant market power in any market; and
- the proposed acquisition was unlikely to provide the merged firm with the ability and incentive to foreclose competing suppliers of latent TB or active TB diagnosis testing products in such a way that would be likely to result in a substantial lessening of competition in any relevant market.
Timeline
| Date | Event |
|---|---|
ACCC commenced review under the Merger Review Process Guidelines. |
|
Closing date for submissions from interested parties. |
|
ACCC announced it would not oppose the proposed acquisition. |